Manicatide M A, Nicolaescu V V, Racoveanu C L, Voiculescu M, Stroescu V
Med Interne. 1977 Oct-Dec;15(4):375-80.
Dexamethasone isonicotinate aerosols were used for the management of 106 patients (33 men, 73 women) with bronchial asthma (mean age 32.7 years); 62 of the patients were steroid-dependent (maintenance dose 1 to 25 mg prednisone/day for 0.5 to 11 years) at the start of the study. A diary of symptoms (including consumption of antiasthmatic drugs) was kept; physical examination and measurement of pulmonary function (peak flow rate, forced expiratory volume in one second) were performed during a one-to-four week control period, as well as at various intervals (up to 14 months) after the start of corticosteroid aerosol therapy. Clinical subjective and objective improvement was accompanied by a significant increase in ventilatory function indices (e.g. the FEV1.0 rose from a control average of 55.5% of predicted to 72% after 4 weeks and 85% after 12 months). The antiasthmatic drug consumption decreased markedly. Administration of systemic steroids could be withdrawn in 49 of the 62 steroid-dependent patients (79%); in the remaining 13 the dose was only lowered. The side-effects were minor (hoarseness of the voice, oropharyngeal candidosis), and limited to a few cases. It is concluded that bronchial asthma can be successfully controlled in four fifths of the patients by very low doses of dexamethasone isonicotinate aerosols, with practically no systemic effects.
地塞米松异烟酸盐气雾剂用于治疗106例支气管哮喘患者（男33例，女73例），平均年龄32.7岁；62例患者在研究开始时依赖类固醇（维持剂量为泼尼松1至25毫克/天，持续0.5至11年）。记录症状日记（包括抗哮喘药物的使用情况）；在1至4周的对照期以及皮质类固醇气雾剂治疗开始后的不同间隔时间（最长14个月）进行体格检查和肺功能测量（峰值流速、一秒用力呼气量）。临床主观和客观改善伴随着通气功能指标的显著增加（例如，一秒用力呼气量从对照时预测值的平均55.5%在4周后升至72%，12个月后升至85%）。抗哮喘药物的使用量显著减少。62例依赖类固醇的患者中有49例（79%）可以停用全身类固醇；其余13例仅降低了剂量。副作用轻微（声音嘶哑、口咽念珠菌病），且仅限于少数病例。得出的结论是，通过极低剂量的地塞米松异烟酸盐气雾剂可以成功控制五分之四患者的支气管哮喘，且几乎没有全身效应。
